Globus Medical Inc. Class A Common Stock vs Sasol Ltd. American Depositary Shares — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Sasol Ltd. American Depositary Shares trades at $15.66 (market cap $9.94B). The key difference: Globus Medical Inc. Class A Common Stock and Sasol Ltd. American Depositary Shares are close in size by market cap, and Sasol Ltd. American Depositary Shares is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Sasol Ltd. American Depositary Shares for 2 Days on average.
| GMED | SSL | |
|---|---|---|
Market Cap | $10.25B | $9.94B |
Volume | 1,108,124 | 1,412,509 |
Sector | Health | Basic Materials |
52-Week High | $96.82 | $15.63 |
52-Week Low | $58.33 | $5.33 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $9.76B | $13.66B |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Sasol (SSL) trades at $15.58, up 1.83% with strong technical momentum and bullish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected revenue growth from $249.1B in 2025 to $272.1B in 2026. Recent developments include a sustainable aviation fuel agreement with White Desert and board changes, while the CFO's stock sales warrant monitoring.
SSL presents a compelling value opportunity with attractive valuation multiples (P/E 13.74, EV/EBITDA 5.45) and 73% analyst buy ratings. However, risks include negative cash flow trends and high RSI levels suggesting potential overbought conditions. The stock's upside depends on continued operational improvements and commodity market stability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Sasol Limited is a Johannesburg-headquartered chemicals and energy company that uses its proprietary Fischer-Tropsch technology to convert coal, natural gas, and crude-oil feedstocks into fuels and chemical products such as polymers, solvents, surfactants, and ammonia, with operations across Southern Africa and international chemical manufacturing sites, including in US.
Read more on SSL →